Jubilant Pharmova’s step down subsidiary -- Jubilant Biosys Innovative Research Services (JBIRSPL) has executed Shareholders’ Agreement and other transition agreements with Pierre Fabre SA, and its affiliate entities (PF), and subscribed to 80% equity capital in JASMIN, with remaining 20% equity capital retained by PF. Simultaneously, the acquisition of PF’s R&D Centre (including R&D Site and R&D activities) at Saint Julien, France by JASMIN stands successfully closed.
JASMIN is a company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS). On closure of transaction, name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL.
JBIRSPL is a subsidiary of Jubilant Biosys, a wholly owned subsidiary of the company.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: